Protalix Initiates Home Care Treatment Program For Gaucher Patients

Protalix has initiated home care treatment program for patients enrolled in the phase-III extension trial of plant-cell expressed recombinant glucocerebrosidase (prGCD).

The phase-III extension trial is a follow-on study to on-going pivotal phase-III clinical trial, which is evaluating the safety and efficacy of prGCD in treatment-naive patients of Gaucher disease.

The home care treatment program allows patients in the phase-III extension trial to receive intravenous treatments of prGCD at home, at a physician’s discretion and under the supervision of a registered nurse.

Upon drug approval, the company plans to continue the program as part of a patient care program designed to assist, support and educate patients receiving prGCD therapy.

Einat Brill-Almon, Senior Vice President of product development, Protalix, said: “We recently enrolled our first patient in the home care treatment program. We feel physician and patients’ willingness to allow prGCD to be administered in the home setting underscores their comfort level with respect to our drug. As we continue to plan for the marketing and commercialization of prGCD, we look forward to rolling out our full patient care program.”